Development and validation of a gene expression tumour classifier for cancer of unknown primary - PubMed (original) (raw)
Development and validation of a gene expression tumour classifier for cancer of unknown primary
Richard W Tothill et al. Pathology. 2015 Jan.
Abstract
Accurate identification of the primary tumour in cancer of unknown primary (CUP) is required for effective treatment selection and improved patient outcomes. The aim of this study was to develop and validate a gene expression tumour classifier and integrate it with histopathology to identify the likely site of origin in CUP.RNA was extracted from 450 formalin fixed, paraffin embedded samples of known origin comprising 18 tumour groups. Whole genome expression analysis was performed using a bead-based array. Classification of the tumours made use of a binary support vector machine, together with recursive feature elimination. A hierarchical tumour classifier was developed and incorporated with conventional histopathology to identify the origins of metastatic tumours.The classifier demonstrated an accuracy of 88% for correctly predicting the tumour type on a validation set of known tumours (n = 94). For CUP samples (n = 49) having a final clinical diagnosis, the classifier improved the accuracy of histology alone for both single and multiple predictions. Furthermore, where histology alone could not suggest any specific diagnosis, the classifier was able to correctly predict the primary site of origin.We demonstrate the integration of gene expression profiling with conventional histopathology to aid the investigation of CUP.
Similar articles
- Efficient identification of miRNAs for classification of tumor origin.
Søkilde R, Vincent M, Møller AK, Hansen A, Høiby PE, Blondal T, Nielsen BS, Daugaard G, Møller S, Litman T. Søkilde R, et al. J Mol Diagn. 2014 Jan;16(1):106-15. doi: 10.1016/j.jmoldx.2013.10.001. Epub 2013 Nov 5. J Mol Diagn. 2014. PMID: 24211363 - An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.
Tothill RW, Kowalczyk A, Rischin D, Bousioutas A, Haviv I, van Laar RK, Waring PM, Zalcberg J, Ward R, Biankin AV, Sutherland RL, Henshall SM, Fong K, Pollack JR, Bowtell DD, Holloway AJ. Tothill RW, et al. Cancer Res. 2005 May 15;65(10):4031-40. doi: 10.1158/0008-5472.CAN-04-3617. Cancer Res. 2005. PMID: 15899792 - An integrated tool for determining the primary origin site of metastatic tumours.
Santos MTD, Souza BF, Cárcano FM, Vidal RO, Scapulatempo-Neto C, Viana CR, Carvalho AL. Santos MTD, et al. J Clin Pathol. 2018 Jul;71(7):584-593. doi: 10.1136/jclinpath-2017-204887. Epub 2017 Dec 16. J Clin Pathol. 2018. PMID: 29248889 Free PMC article. - [Molecular diagnostic methods designed for clinical approach to cancer of unknown origin].
Fujita Y, Nishio K. Fujita Y, et al. Gan To Kagaku Ryoho. 2009 Jun;36(6):923-6. Gan To Kagaku Ryoho. 2009. PMID: 19542713 Review. Japanese. - Hunting the primary: novel strategies for defining the origin of tumours.
Dennis JL, Oien KA. Dennis JL, et al. J Pathol. 2005 Jan;205(2):236-47. doi: 10.1002/path.1702. J Pathol. 2005. PMID: 15641019 Review.
Cited by
- A review on trends in development and translation of omics signatures in cancer.
Ma W, Tang W, Kwok JSL, Tong AHY, Lo CWS, Chu ATW, Chung BHY; Hong Kong Genome Project. Ma W, et al. Comput Struct Biotechnol J. 2024 Feb 3;23:954-971. doi: 10.1016/j.csbj.2024.01.024. eCollection 2024 Dec. Comput Struct Biotechnol J. 2024. PMID: 38385061 Free PMC article. Review. - New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges.
Ma W, Wu H, Chen Y, Xu H, Jiang J, Du B, Wan M, Ma X, Chen X, Lin L, Su X, Bao X, Shen Y, Xu N, Ruan J, Jiang H, Ding Y. Ma W, et al. Brief Bioinform. 2024 Jan 22;25(2):bbae028. doi: 10.1093/bib/bbae028. Brief Bioinform. 2024. PMID: 38343328 Free PMC article. Review. - A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.
Posner A, Prall OW, Sivakumaran T, Etemadamoghadam D, Thio N, Pattison A, Balachander S, Fisher K, Webb S, Wood C, DeFazio A, Wilcken N, Gao B, Karapetis CS, Singh M, Collins IM, Richardson G, Steer C, Warren M, Karanth N, Wright G, Williams S, George J, Hicks RJ, Boussioutas A, Gill AJ, Solomon BJ, Xu H, Fellowes A, Fox SB, Schofield P, Bowtell D, Mileshkin L, Tothill RW. Posner A, et al. J Pathol. 2023 Jan;259(1):81-92. doi: 10.1002/path.6022. Epub 2022 Nov 30. J Pathol. 2023. PMID: 36287571 Free PMC article. - Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity.
Möhrmann L, Werner M, Oleś M, Mock A, Uhrig S, Jahn A, Kreutzfeldt S, Fröhlich M, Hutter B, Paramasivam N, Richter D, Beck K, Winter U, Pfütze K, Heilig CE, Teleanu V, Lipka DB, Zapatka M, Hanf D, List C, Allgäuer M, Penzel R, Rüter G, Jelas I, Hamacher R, Falkenhorst J, Wagner S, Brandts CH, Boerries M, Illert AL, Metzeler KH, Westphalen CB, Desuki A, Kindler T, Folprecht G, Weichert W, Brors B, Stenzinger A, Schröck E, Hübschmann D, Horak P, Heining C, Fröhling S, Glimm H. Möhrmann L, et al. Nat Commun. 2022 Aug 2;13(1):4485. doi: 10.1038/s41467-022-31866-4. Nat Commun. 2022. PMID: 35918329 Free PMC article. - Psychological distress, understanding of cancer and illness uncertainty in patients with Cancer of Unknown Primary.
Wolyniec K, Sharp J, Fisher K, Tothill RW, Bowtell D, Mileshkin L, Schofield P. Wolyniec K, et al. Psychooncology. 2022 Nov;31(11):1869-1876. doi: 10.1002/pon.5990. Epub 2022 Jul 3. Psychooncology. 2022. PMID: 35765251 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources